CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer

Publication

CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer

Powles, T.
;
Mendez-Vidal, M. J.
;
Rodriguez-Vida, A.
;
Perez-Valderrama, B.
;
Esteban, E.
;
Thistlethwaite, Fiona C
;
Patel, P. M.
;
Herranz, U. A.
;
Srinivasan, G.
;
Hamid, A.
... show 9 more

Authors

Powles, T.
Mendez-Vidal, M. J.
Rodriguez-Vida, A.
Perez-Valderrama, B.
Esteban, E.
Thistlethwaite, Fiona C
Patel, P. M.
Herranz, U. A.
Srinivasan, G.
Hamid, A.
Larkin, J.
Ralph, C.
Symeonides, S. N.
Puente, J.
Hartmaier, R.
Markovets, A.
Prendergast, A.
Mousa, K.
Suarez, C.

Affiliation

Barts ECMC, Barts Cancer Institute, Queen Mary University of London, London

Date

2022

Collections

All Christie Publications

Show all metadata

Type

Meetings and Proceedings

Citation

Powles T, Mendez-Vidal MJ, Rodriguez-Vida A, Perez-Valderrama B, Esteban E, Thistlethwaite F, et al. CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer. Journal of Clinical Oncology. 2022 Jun;40(17). PubMed PMID: WOS:000891791500023.

URI

http://hdl.handle.net/10541/626047